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In Brief
Bellier et al. demonstrate that MGO stress is a constant feature of KRAS-mutated CRC tumors. MGO induces a key survival pathway implicated in resistance to EGFR-targeted therapy in CRC. The scavenging of this oncometabolite could be beneficial in the treatment of both wildtype and mutant KRAS CRC tumors.
INTRODUCTION
Cancer cells undergo an adaptive metabolic shift, known as the Warburg effect, toward increased use of aerobic glycolysis when compared with normal cells. In addition to produce ATP, the glycolytic pathway provides metabolic intermediates needed for cell growth and proliferation (Vander Heiden and DeBerardinis, 2017) . One unavoidable consequence associated with elevated glycolytic flux is the spontaneous formation of methylglyoxal (MGO) from triose phosphate intermediates (Richard, 1993) . MGO is a highly reactive dicarbonyl compound that glycates proteins, DNA, and lipids much more efficiently than glucose (Brownlee, 2001; Maessen et al., 2015; Thornalley et al., 1995) . MGO post-translational modification of arginine residues notably leads to the formation of argpyrimidine and dihydroxy-imidazolone (MGO-Hs) protein adducts (Rabbani and Thornalley, 2012a) . Heat shock proteins are direct targets of MGO glycation, with heat shock protein 27 (Hsp27) being the best-characterized argpyrimidine detected in several cancer types, including human colorectal cancer (CRC). MGO-modified Hsp27 (MGO-Hsp27) is more stable and active than native Hsp27 and favors cancer cell escape from apoptosis (Oya-Ito et al., 2006; Sakamoto et al., 2002; van Heijst et al., 2006) .
MGO is efficiently detoxified to D-lactate by glyoxalase 1 (GLO1), an ubiquitous cellular enzyme (Rabbani and Thornalley, 2012b) . Using a GLO1-silencing strategy, we previously demonstrated that the direct modification of Hsp90 by MGO favors YAP nuclear localization and the inactivation of the Hippo tumor suppressor pathway in breast cancer cells . We showed that MGO stress endowed breast cancer cells with enhanced growth and metastatic potential, both of which were efficiently blocked in vivo using MGO scavenger molecules such as carnosine (beta alanyl-L-histidine) and aminoguanidine (Nokin et al., , 2019 . MGO is cytotoxic and mutagenic, and several studies demonstrated the pro-apoptotic effect of MGO stress on cancer cells. In fact, we recently contributed to reveal the dual role of MGO stress by demonstrating its hormetic effect on cancer cells, with low concentrations supporting tumor growth and high levels inducing toxicity and apoptotic death .
KRAS mutation represents one of the most prevalent genetic alterations in cancers. In CRC tumors, $85%-90% of KRAS mutations occur in exon 2, with codon 12 and 13 being the most predominant mutations. In particular, KRAS G12V mutation is associated with resistance to apoptosis through AKT activation (Alamo et al., 2015; Guerrero et al., 2000) , higher metastatic potential (Alamo et al., 2015) , and mitochondrial dysfunction leading to glycolytic reprogramming (Hu et al., 2012) . Cetuximab anti-epidermal growth factor receptor (anti-EGFR) therapy is aimed at the targeting of the two major pathways activated through EGFR. The RAS/RAF/MEK/ERK pathway, which controls gene transcription, cell-cycle progression, and cell proliferation, and the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which activates a cascade of anti-apoptotic and prosurvival signals. The molecular mechanisms that contribute to the development of primary and secondary resistance to cetuximab in CRC are the subject of intensive clinical and research studies in order to propose new combined modality approaches (Bardelli and Siena, 2010; De Roock et al., 2011; Hong et al., 2016) . The detection of KRAS mutation rapidly revealed to be a strong and useful negative predictive biomarker of CRC response to cetuximab (Allegra et al., 2016; Liè vre et al., 2006) .
Parallel activation of RAS and PI3K pathways (for review, see Castellano and Downward, 2011) confers maximal resistance to cetuximab (Jhawer et al., 2008) and points to PI3K/AKT activation as a crucial player in CRC resistance to targeted EGFR therapy. Direct interaction of activated KRAS with PI3K subunit p110 (Downward, 2003; Gupta et al., 2007; Rodriguez-Viciana et al., 1994) has been proposed to explain the constitutive activation of the PI3K/AKT pathway in a KRAS-mutated setting and its crucial role in KRAS-mediated transformation. However, it is noteworthy that in CRC, the knockdown of KRAS in mutant cell lines did not suppress AKT phosphorylation and led to the discovery of other dominant mechanisms underlying AKT activation in a KRAS-mutated setting, such as specific tyrosine kinase receptor signaling (i.e., insulin-like growth factor I receptor) (Ebi et al., 2011) . A better understanding of how AKT signaling is activated in KRAS mutant CRC will point to potential therapeutic strategies against these tumors refractory to EGFR-targeted therapy.
Our previous demonstration of elevated MGO adducts in human CRC tumors presenting high FDG-PET (fluorodeoxyglucose positron emission tomography) metabolic activity (Chiavarina et al., 2017) and the glycolytic switch shown to occur in KRAS mutant CRC cells (Hu et al., 2012) prompted us to (1) assess endogenous MGO stress in KRAS-mutated tumors and cell lines and (2) envisage the possibility that MGO scavengers could resensitize mutant KRAS tumors to cetuximab.
Using two series of human CRC tumors, we found that the majority of KRAS G12V tumors presented high MGO stress and that this latter correlated with the detection of phosphorylated AKT (P-AKT). We used SW48 and LIM1215 isogenic human CRC models, consisting of targeted heterozygous knockin of KRAS G12V , to compare KRAS-mutated cells to their wild-type counterparts (KRAS WT ), which do not harbor other frequent CRC oncogenic mutations (i.e., PTEN, NRAS, BRAF, and PIK3CA). Such models elude variability of the genetic background between CRC cell lines that confounds attribution of results directly to the presence of mutant KRAS. We found elevated MGO levels and adducts in KRAS G12V when compared with KRAS WT cells. Exogenous and endogenous (GLO1 silencing) MGO stress induced a significant activation of AKT, in wild-type and mutant KRAS, that was abrogated using MGO scavengers. In vitro, the combination of cetuximab and carnosine inhibited KRAS-mutated tumor growth. Importantly, the sole MGO stress induction in cetuximab-sensitive KRAS WT A Figure 1 . Evidence of MGO Dicarbonyl Stress in KRAS-Mutated Human CRC Tumors (A) Detection of MGO adducts as assessed by IHC of argpyrimidines in a series of colon cancer tumors (n = 48). Two representative KRAS WT and KRAS G12V mutated CRC tumors are shown. Data are shown as percentage of tumors presenting MGO stress in KRAS WT and KRAS G12V tumors and were analyzed using a chi-square contingency test (p = 0.0001). The lower images show the area within the dashed rectangle on the upper images at higher magnification. Scale bars represent 100 mm. See also Figure S1 . CRC cells rendered them resistant. Therefore, MGO stress, which we prove to be implicated in KRAS-mutated resistance, should be also taken into account when predicting the efficacy of EGFR-targeted drugs in a wild-type CRC clinical setting.
RESULTS

Evidence of MGO Dicarbonyl Stress in KRAS-Mutated CRC Human Tumors and Cell Lines
In glycolytic cells, MGO production and the formation of protein adducts generate MGO dicarbonyl stress conditions. We previously demonstrated that elevated MGO adducts are detected in human CRC malignant lesions when compared with matched normal colon and are correlated with a pathological stage (Chiavarina et al., 2017) . Using immunohistochemistry (IHC), we specifically evaluated the levels of MGO adducts in KRAS WT and KRAS-mutated (KRAS G12V ) CRC tumors (n = 48). MGO adducts were mainly detectable in the cytoplasm of cancer cells (Figure 1A) . Remarkably, both differentiated and stroma infiltrating tumor cells displayed detectable MGO adducts in KRAS G12V tumors ( Figure 1A) . The intensity and extent of the immunostaining were scored, and tumor MGO dicarbonyl stress was evaluated as high or low, as detailed in STAR Methods. The majority of KRAS G12V tumors displayed high MGO dicarbonyl stress when compared with KRAS WT tumors (chi-square test, p = 0.0001) ( Figure 1A) . We observed a similar correlation between KRAS mutation and MGO stress using a series of 84 rectal human tumors (Fisher's test, p = 0.03) that we previously characterized for their KRAS status (Lovinfosse et al., 2016 ) ( Figure S1A ).
KRAS G12V Cells Are More Glycolytic than Isogenic Wild-Type CRC Cells
We used SW48 and LIM1215 isogenic CRC models to systematically characterize the effects of KRAS mutation on cell glycolytic phenotype. First, the quantitative measurement of the glycolytic rate of SW48 and LIM1215 cells demonstrated that KRAS G12V cells presented a significantly higher glycolytic capacity upon glucose challenge than KRAS WT cells (Figures 2A and 2B, respectively) . Glycolytic, maximal, and spare ECAR (extracellular acidification rate) notably indicated that KRAS G12V rely more on glycolysis than KRAS WT cells in both SW48 and LIM1215 models (Figures 2A and 2B , respectively). Accordingly, GLUT1 glucose transporter expression was significantly elevated in KRASmutated cells ( Figures 2C and 2D ). Second, we evaluated the expression of key glycolysis cascade enzymes in KRAS WT versus KRAS G12V cells. Critical regulatory enzymes in glycolytic control, including hexokinase II (HK II), PFKB3, the active M2 splice variant of pyruvate kinase (P-PKM2), and inactive pyruvate dehydrogenase (P-PDH) presented with higher basal expression levels in KRAS G12V cells than in KRAS WT cells in the SW48 ( Figure 2C ) and LIM1215 ( Figure 2D ) models. Third, 13 C-labeled glucose flux analysis confirmed enhanced glucose uptake and elevated amounts of the first intermediates of the glycolysis pathway (Figure 2E) in SW48 KRAS G12V cells ( Figure 2F ). Taken together, these results indicate that KRAS G12V cells present a rewired glucose metabolism promoted by the overexpression of key effectors of the glycolytic pathway. These data and our previous demonstration of MGO adducts accumulation in high 18 F-FDG-PET CRC tumors (Chiavarina et al., 2017) urged us to characterize for the first time MGO stress in the context of mutant KRAS CRC cells.
Glycolytic Mutant KRAS Cells Produce Higher Amounts of MGO than Isogenic Wild-Type CRC Cells
In good accordance with their glycolytic phenotype, KRAS G12V SW48 and LIM1215 cells showed a higher level of MGO than KRAS WT cells, as measured in their conditioned media using liquid chromatography-tandem mass spectrometry (LC-MS/ MS) ( Figure 3A ). Using this technique, we also detected 13 C-labeled MGO in CRC cells challenged with 13 C-glucose, thus providing the first evidence of MGO being a glycolysis byproduct detectable in cancer cells and secreted in the medium ( Figure 3B ). Higher accumulation of MGO adducts (argpyrimidines and MG-Hs) was detected in KRAS G12V SW48 ( Figure 3C ) and LIM1215 ( Figure 3C ) cells when compared with KRAS WT isogenic cells. GLO1 expression ( Figure 3E ), GLO1 enzymatic activity ( Figure 3F ), and D-lactate production ( Figure S2A ) were similar in KRAS WT and KRAS G12V settings. Accordingly, exogenous MGO was detoxified into D-lactate by GLO1 with comparable efficiency independently of KRAS status ( Figure S2B ). Altogether, these data indicate that elevated MGO and MGO adducts levels observed in KRAS-mutated cells are likely related to their favored usage of glycolysis, since their GLO1 detoxification capacity is comparable to the one observed in KRAS WT cells.
MGO Stress Induces AKT Activation in CRC Cells that Is Reverted Using MGO Scavengers
The activation of AKT promotes glucose uptake and stimulates aerobic glycolysis in cancer cells (Elstrom et al., 2004; Rathmell et al., 2003) . We next observed that basal levels of P-AKT and its downstream targets, P-GSK3beta and P-P70S6K, were consistently elevated in KRAS G12V cells compared with KRAS WT cells ( Figure 4A ). To check whether this marked difference in AKT activation could be related to MGO stress conditions, we treated the cells with two potent MGO scavengers. Both carnosine ( Figure 4B ) and aminoguanidine ( Figure 4C ) significantly decreased P-AKT levels in both KRAS WT and KRAS G12V cells, thus confirming the implication, at least in part, of MGO stress in the regulation of AKT activity. To support this important observation, we next reasoned that exogenous MGO treatment should induce AKT activation in CRC cells. In isogenic models ( Figure 4D ), it is remarkable that MGO treatment induced a dose-dependent P-AKT activation (C and D) GLUT1, HXII, PFKFB3, P-PKM2, PKM2, P-PDH, and PDH levels were assessed in SW48 CRC cells (C) and LIM1215 CRC cells (D) using western blot. A representative western blot of at least two independent experiments is shown. b-Actin was used for normalization. (E) Schematic representation of the first steps of glycolysis and MGO production. (legend continued on next page) in KRAS WT cells. In KRAS G12V cells, the highest doses of MGO also increased P-AKT level over the high basal levels constantly detected in these cells. Elevated intracellular MGO levels were evidenced upon MGO treatment in CRC cells using methyl diaminobenzene-BODIPY (MBo), a fluorescent sensor of MGO (Wang et al., 2013 ) ( Figure S3A ). It is noteworthy that MGO induced significant activation of AKT in a panel of human CRC cell lines (i.e., HT29, SW480, HCT116, and Lovo) ( Figure 4E ) regardless of their mutational profile ( Figure 4F ), thus establishing a link between MGO stress and AKT activation. Consistently, we found that a majority of high-P-AKT CRC tumors presented with high MGO stress when compared with low-P-AKT tumors (Fisher's test, p = 0.03) ( Figure 4G ). Remarkably, the sole induction of an endogenous MGO stress through the inhibition of GLO1 expression using specific small interfering RNAs (siRNAs) recapitulated AKT activation in the SW48 isogenic model ( Figure 4H ). Increased MGO levels were detected in GLO1 silenced SW48 cells when compared with control cells using both the MBo fluorescent sensor of MGO ( Figure S3B ) and LC-MS/MS ( Figure S3C ). Sustaining further the relationship between de novo MGO stress induction and P-AKT levels is the fact that the co-treatment with MGO and its scavengers, carnosine ( Figure 4I ) and aminoguanidine ( Figure 4J ), effectively reversed MGO-mediated AKT activation in CRC cells. The significant decrease of MGO levels was verified in carnosine-and aminoguanidine-treated SW48 cells using LC-MS/MS ( Figure S3D ).
MGO-Mediated Activation of AKT Occurs through PI3K and mTORC2 in CRC Cells
In order to explore the molecular mechanisms underlying MGOmediated AKT phosphorylation, we first checked the possibility that MGO could regulate PI3K upstream of AKT activation. We observed that MGO treatment induced the activation of PI3K in KRAS WT CRC cells and KRAS G12V LIM1215 cells ( Figure 5A ). Next, we focused on the mammalian target of rapamycin 2 (mTORC2), because this complex directly phosphorylates AKT on Ser473 (Sarbassov et al., 2005) . We found that MGO treatment was sufficient to induce the expression of the mTORC2 components Rictor and mTOR in KRAS WT CRC cells ( Figure 5B ). MGO induction of mTORC2 was not significant in KRAS G12V CRC cells (data not shown), possibly because of their high basal level of mTORC2 complex when compared with KRAS WT cells that is likely attributable to the direct binding and activation of mTORC2 by mutated RAS, as reported recently (Kovalski et al., 2019) . Importantly, the use of torin 1 (an mTORC1 and mTORC2 inhibitor) completely blocked MGO-mediated AKT activation, while rapamycin (an mTORC1 inhibitor) did not ( Figures 5C and 5D ) in KRAS WT and KRAS G12V settings in both isogenic models. These data demonstrate that MGO acts as a potent inducer of AKT activation through the PI3K/ mTORC2 axis.
High MGO-Glycated Hsp27 (MGO-Hsp27) Sustains AKT Activation in KRAS G12V Cells To explore the molecular mechanism(s) underlying the link evidenced between MGO stress and AKT activation, we next envisaged the possibility that Hsp27 could be implicated, knowing that (1) MGO -glycated Hsp27 (MGO-Hsp27) in cancer cells supports their escape from apoptosis (Oya-Ito et al., 2011; Sakamoto et al., 2002) , (2) Hsp27 chaperone activity has been associated with the resistance to different cytotoxic agents (Kamada et al., 2007; Kuramitsu et al., 2012; Mori-Iwamoto et al., 2007) , and (3) Hsp27 has been shown to control apoptosis by regulating AKT activation (Rane et al., 2003) . First, we undertook the detection of MGO-Hsp27 in SW48 isogenic model. Immunoprecipitation (IP) of argpyrimidine MGO adducts in KRAS WT and KRAS G12V cells evidenced Hsp27 detection using western blotting and confirmed the presence of MGO-Hsp27 in these cells, with significantly elevated amounts in KRAS G12V when compared with KRAS WT cells ( Figure 5E ). Consistently, the reverse IP experiment using anti-Hsp27 antibody allowed the detection of an argpyrimidine adduct of the expected molecular weight ($27 kDa) ( Figure 5F ). Interestingly, the screening of a series of human CRC cell lines showed that elevated amounts of MGO-Hsp27 paralleled high P-AKT levels ( Figure 5G ). At this point, our observations let us envisage that activation of AKT in CRC cells is associated with MGO stress and high MGO-Hsp27 levels. Previous studies demonstrated that MGO-Hsp27 is more prone to form stable and functional oligomers than its native form (Oya-Ito et al., 2011; Sakamoto et al., 2002) . Our in vitro glycation of recombinant human Hsp27 (rhHsp27) by MGO (500 mM) notably favored the formation of MGO-Hsp27 dimers that were present endogenously and detectable in KRAS G12V , but not in KRAS WT , protein extracts ( Figure S4A ). Knowing that Hsp27 plays a role in AKT activation, we aimed at exploring further the marked difference between KRAS G12V and KRAS WT cells in term of MGO-Hsp27 level. We used cycloheximide to block protein synthesis and measure the half-life of Hsp27 in the SW48 model. In KRAS WT cells, total Hsp27 (with predominantly native Hsp27) decreased rapidly with time (halflife was reached after 7.3 h) when compared with total Hsp27 level (with predominantly MGO-Hsp27) of KRAS G12V cells, which showed elevated and stable levels, as shown in Figure S4B and quantified in Figure S4C . The specific detection of MGO-Hsp27 level further completed this observation, as MGO-Hsp27 was detected in both cell lines all along cycloheximide challenge ( Figure S4B ). In KRAS WT cells, the decrease of total Hsp27 in favor of cellular enrichment in stable MGO-Hsp27 was associated with the specific increase of P-AKT levels ( Figure S4B ). The relationship revealed between MGO-Hsp27 and AKT activation was further assessed in experiments where BioPORTER reagent was used to deliver rhHsp27 or its in vitro glycated form, MGO-rhHsp27, into cells by endocytosis. We observed a significant increase of P-AKT upon MGO-rhHsp27 delivery to (E) GLO1 protein levels assessed in CRC cells using western blot. b-Actin was used for normalization. A representative western blot of at least three independent experiments is shown. (legend continued on next page) SW48 KRAS WT cells ( Figure 5H ). Next, we used specific siRNAs directed against Hsp27 in KRAS WT and KRAS G12V cells treated with MGO. In the absence of MGO-Hsp27, exogenous MGO treatment was less efficient at inducing P-AKT ( Figure 5I ). The ultimate demonstration of the role of endogenous MGO-Hsp27 in AKT activation arose from carnosine ( Figure 5J ) and aminoguanidine ( Figure 5K ) treatments, which induced a significant decrease of MGO-Hsp27 in KRAS G12V cells that was paralleled by P-AKT inhibition in CRC cells.
Carnosine Specifically Inhibits KRAS G12V Cell Clonogenic Potential In Vitro and Tumor Growth In Vivo After having established the potent effect of carnosine as an inhibitor of AKT activity in CRC cells. We next aimed at demonstrating the crucial dependence of KRAS-mutated CRC cells on AKT for their survival. In fact, significantly lower concentrations of LY294002 and BYL719 (PI3K inhibitors) and MK2206 (AKT inhibitor) were necessary to decrease by half the viability of KRAS-mutated cells when compared with wild-type cells (Figure 6A) . KRAS G12V showed a significant apoptotic death when challenged with PI3K/AKT inhibition, while KRAS WT cells did not ( Figure 6B ), thus validating the higher dependency of KRAS-mutated cells on AKT activation. Efficient inhibition of AKT phosphorylation in presence of each inhibitor is shown in Figure S5A . We next compared the capacity for continued proliferation of KRAS WT and KRAS G12V cells in presence of carnosine. Clonogenic assay performed on SW48 model showed a lower capacity of KRAS G12V cells to produce colonies in presence of carnosine when compared with KRAS WT (Figure 6C ). Accordingly, KRAS G12V cells proved to be significantly more sensitive to carnosine treatment in comparison with KRAS WT cells (Figure 6D ). Carnosine provoked a 2.3-fold increase of apoptosis in SW48 KRAS G12V as assessed using Annexin V assay (Figure 6E) , while KRAS WT did not show any significant apoptosis change at the same dose. Likewise, aminoguanidine treatment induced apoptosis only in KRAS-mutated cells ( Figure 6E ). In presence of both MGO scavengers ( Figure 6F ), KRAS G12V cells showed a strong increase of cleaved poly (ADP-ribose) polymerase (PARP) and cleaved caspase 3 apoptosis markers. Evidence sustaining carnosine pro-apoptotic effect via AKT inhibition was brought using SC-79, a specific AKT activator. The effect of SC-79 on carnosine-induced apoptosis was evaluated by pretreating KRAS G12V cells with increasing doses of SC-79 beginning 2 h before the addition of carnosine. The percentage of apoptotic cells was globally decreased in the presence of SC-79 and reached significance at the higher dose used ( Figure 6G ), thus demonstrating that carnosine cytotoxicity occurred, at least in part, via AKT inhibition in KRAS-mutated cells. The efficacy of SC-79 at inducing P-AKT was verified by western blotting ( Figure S5B ).
We next tested carnosine's effect on the growth of subcutaneous SW48 KRAS G12V and KRAS WT xenografts in mice. Remark-ably, intraperitoneal injections of carnosine induced a significant decrease in KRAS G12V tumor growth but had no impact on KRAS WT cells ( Figure 6H ). MGO adducts, Hsp27, P-AKT, and Ki67 IHC detection performed on experimental tumors showed a consistent decrease in KRAS G12V tumors treated with carnosine and brought their levels to those of KRAS WT cells ( Figures  6I) . These in vivo data are in good complementarity with in vitro observations, as they point to the particular reliance of KRAS G12V cells on MGO stress and demonstrate the anti-tumor efficacy of carnosine against KRAS-mutated CRC tumors.
Carnosine Resensitizes KRAS-Mutated CRC Cells to Cetuximab In Vitro and In Vivo Our demonstration of the importance of MGO stress for KRAS G12V survival and tumor growth prompted us to test the possibility that carnosine could resensitize KRAS-mutated CRC cells when used in combination with cetuximab. As expected, cetuximab treatment of SW48 KRAS G12V cells did not induce a significant increase of their apoptotic rate ( Figure 7A ). In comparison, carnosine tripled the proportion of apoptotic cells. Moreover, co-treatment with cetuximab and carnosine proved to be more efficient than each treatment considered alone ( Figure 7A) . Thus, the shutdown of the AKT major survival pathway using carnosine resensitized KRAS-mutated cells to cetuximab. Enhanced apoptosis upon combined treatment was further underlined by increased PARP cleavage and caspase 3 ( Figure 7B ). To strengthen these important conclusions, we next conducted in vivo experiments where we treated mice bearing KRAS-mutated SW48 ( Figure 7C ), HCT116 ( Figure 7D ), and LIM1215 ( Figure 7E ) tumors with both cetuximab and carnosine. Combined treatment showed a significant blockade of tumor growth compared with separate cetuximab and carnosine treatments. Altogether, these data support the rationale for combining cetuximab with MGO scavenger molecules in the mutant KRAS CRC genetic setting.
Induction of MGO Stress Renders Sensitive LIM1215 Cells Resistant to Cetuximab
Based on these results, we reasoned that the induction of MGO stress in KRAS WT LIM1215 cells that are sensitive to cetuximab should induce P-AKT and ultimately decrease their sensitivity to cetuximab. To test this hypothesis, we generated KRAS WT LIM1215 cells stably depleted for GLO1 using specific small hairpin RNAs (shRNAs). In these cells, the induction of endogenous MGO stress was evidenced by the detection of MGO adducts ( Figure 7F ) and intracellular MGO level quantification using MBo probe ( Figure 7G ). MGO-stressed cells showed a significant induction of P-AKT ( Figure 7H ) and proved to be resistant to cetuximab, as demonstrated by their respective growth curves ( Figure 7I ) and cetuximab half-maximal inhibitory concentration (IC 50 ) calculation ( Figure 7J ). Collectively, these data indicate that MGO stress induces AKT activation and confers resistance to cetuximab in wild-type KRAS CRC cells. In fact, the MGO (H) P-AKT induction was assessed upon GLO1 silencing using two siRNAs in CRC cells. Efficient GLO1 silencing is shown. (I and J) The induction of P-AKT by MGO is reverted by carnosine (I) and aminoguanidine (J) after 3 h of co-treatment in CRC cells. All immunoblots were normalized for b-actin and are representative of at least three independent experiments. See also Figure S3 . (legend continued on next page) stress condition recapitulates by itself the features of mutant KRAS resistance to cetuximab and therefore could explain, at least in part, the lack of efficacy of this drug in the majority of advanced CRC patients with wild-type KRAS tumors.
DISCUSSION
Energetic metabolism adaptation is a characteristic feature of cancer (Hanahan and Weinberg, 2011) . Metabolic pathways such as glycolysis are notably rewired in order to divert glucose into anabolic pathways to satisfy the demand for cellular building blocks (Vander Heiden et al., 2009 ). These last decades, the study of oncometabolites such as MGO has attracted much interest, as they point to cancer cell properties that could be therapeutically exploited in different types of cancer (Sullivan et al., 2016) . Changes in the levels of specific metabolites have been implicated in cancer initiation, progression, and drug resistance. The reprogramming of tumor metabolism is notably under the control of oncogenic signals. In particular, the RAS oncogene has been shown to promote glycolysis (Racker et al., 1985; Yun et al., 2009) . MGO levels in cancer cells result from the balance between MGO formation, mainly as a by-product of glycolysis, and its detoxification by the glyoxalase system (Bellahcè ne et al., 2018) . In this study, we demonstrate that mutant KRAS tumors showed elevated MGO adducts when compared with wildtype KRAS CRC tumors. KRAS G12V and KRAS WT isogenic CRC cell lines presented with similar GLO1 detoxification activity, thus indicating that it is MGO production and adducts formation that are favored in mutant-KRAS cells. Consistently, glucose tracing experiments proved that the glycolytic flux is intensified in mutant KRAS when compared with wild-type cells and that glucose is the main source of MGO in CRC cells. The concept defining cancer cell dependence on glycolysis to resist to targeted therapy has been well documented in melanoma. Indeed, BRAF inhibitors possess anti-glycolytic activity, and glucose metabolism is restored upon development of acquired resistance in melanoma (Hardeman et al., 2017; Parmenter et al., 2014) . Consistently, cetuximab proved to reverse the Warburg effect in head and neck squamous cell carcinoma (HNSCC) through HIF-1 alpha inhibition, and HNSCC cells with acquired cetuximab resistance expressed high HIF-1 alpha levels and were highly glycolytic (Lu et al., 2013) .
We demonstrated that an important consequence of the MGO stress condition in CRC cells is the activation of AKT signaling. MGO consistently increased the phosphorylation of AKT, even over a high basal level, in all CRC cell lines analyzed independently of their mutational profile. AKT activation was reversed using MGO scavengers, thus establishing a direct link between MGO oncometabolite and this key pro-survival signaling pathway in CRC. We have shown that KRAS G12V cells rely on the PI3K/AKT pathway for their survival and that experimental tumors show significantly decreased growth inhibition in the presence of carnosine. On the contrary, KRAS WT tumors and cells presented with low MGO stress and P-AKT and were less dependent on AKT activity for their survival. Accordingly, they proved to be insensitive to MGO stress blockade when xenografted in mice.
Approximately one-fourth of human CRC tumors harbor mutations in both KRAS and PI3KCA (Parsons et al., 2005) . The selective advantage conferred by such apparently redundant signalization has been notably associated with an aggravated resistance to anti-EGFR therapy (Jhawer et al., 2008) and the suppression of oncogene-induced senescence (Kennedy et al., 2011) . In the context of MGO stress, another non-negligible benefit from AKT activation is its well-known role as a driver of the Warburg effect. For example, AKT triggers increased glucose uptake through the upregulation of glucose transporters (Elstrom et al., 2004; Courtnay et al., 2015) , resulting in enhanced glycolytic flux, cell growth, and survival (Robey and Hay, 2009 ). These observations let us propose a vicious cycle where MGO stress triggers AKT activity that in turn sustains the glycolytic flux, which then produces more MGO in cancer cells.
Cetuximab therapy is aimed at targeting the major pathways activated through EGFR. Based on their screening of 22 CRC cell lines for cetuximab response, Jhawer and collaborators (Jhawer et al., 2008) concluded that the cell lines that acquire constitutive activation of the PI3K/AKT pathway have a diminished dependence on canonical EGFR-ligand-induced signaling and are more resistant to cetuximab. One important finding of our study is that sensitive KRAS WT cells that undergo MGO stress switch to a dominant AKT dependence for their survival and become resistant to cetuximab. Altogether, these results not only point to pro-survival signals induced by MGO stress contributing, at least in part, to cetuximab resistance in mutant KRAS condition but also provide essential information for understanding the resistance to EGFR-targeted therapy reported in wild-type KRAS clinical setting. In fact, up to 50% of patients with wild-type KRAS tumors are resistant to cetuximab, and the quest for predictive biomarkers and new therapeutic targets is still the object of intense research (De Roock et al., 2011; Salgado et al., 2018) . We propose MGO-mediated AKT activation as an additional mechanism of resistance to cetuximab that does not involve the well-described genetic alterations affecting downstream and cross-talk effectors of EGFR signaling shown to negatively affect sensitivity to EGFR inhibitors (De Roock et al., 2010; Di Nicolantonio et al., 2008; Sartore-Bianchi et al., 2009) . It would be interesting to check whether MGO stress status could predict, among quadruple wild-type CRC tumors (F) Reverse IP using anti-Hsp27 allowed the detection of an~27-kDa argpyrimidine adduct corresponding to MGO-Hsp27. (legend continued on next page) (KRAS/NRAS/BRAF/PI3KCA), those that display MGO-induced dependence on PI3K/AKT for their survival and will be refractory to cetuximab treatment but sensitive to MGO blockade. The accumulated evidence indicates that the mechanisms that cause primary resistance can also be responsible of acquired resistance to cetuximab (i.e., HER2 and MET amplifications and genetic alterations of RAS/RAF/MEK) (Bray et al., 2019; Li et al., 2019; Troiani et al., 2016; Van Emburgh et al., 2014) . We cannot exclude that MGO-mediated AKT activation occurring upon glycolytic switch (triggered by KRAS mutation or other mechanisms) could also play a role in acquired resistance to EGFRtargeted therapies in CRC. Reliable preclinical models recently validated such as xenospheroids generated from patient-derived xenografts (Luraghi et al., 2018) will prove very useful to broaden our understanding of the role of glycolysis-induced MGO stress in acquired resistance to anti-EGFR therapy in CRC.
Being a critical regulator of AKT activity, mTORC2 protein kinase lately gained more attention as a key player in cancer cell survival, energetic metabolism, and proliferation. We show that MGO-stress-mediated AKT activation depends, at least in part, on the induction of mTORC2 expression in CRC cells. These findings provide with an unanticipated mechanism of regulation of mTORC2, which receives inputs mainly from growth factors and cytokines. Mechanistically, we also demonstrated that endogenous and exogenous MGO stress induces AKT activation that is lost upon Hsp27 silencing. AKT is a known target for Hsp27 chaperone activity, which prevents its dephosphorylation and degradation, hence promoting its stability and activation (Mearow et al., 2002) . Hsp27 expression is increased in a variety of malignancies, including gastric (Huang et al., 2010) and pancreatic (Melle et al., 2007) cancers, and its overexpression is a bad prognostic factor in CRC (Han et al., 2018; Yu et al., 2010) . MGO modification of Hsp27 has been previously shown to be essential to its repressing activity on caspase activation and cancer cell evasion from apoptosis (Oya-Ito et al., 2011; Sakamoto et al., 2002; van Heijst et al., 2006) . Our demonstration of high levels of stable MGO-Hsp27 in mutant KRAS CRC cells appears to be of crucial importance in the context of their resistance to anti-EGFR therapy. Taken collectively, these studies and ours let us propose that the detection of global MGO adducts levels or specific MGO stress adducts such as MGO-Hsp27 could represent an interesting prediction tool to help stratify patients likely to benefit from anti-EGFR therapy.
Given the difficulties associated with directly inhibiting the KRAS oncoprotein, treating mutant KRAS CRC remains a major challenge. EGFR signaling represents the main convergent pathway that is intensively explored in preclinical studies and clinical trials for a better understanding of anti-EGFR therapy resistance in CRC. The complexity of the EGFR/MEK/ERK signaling network involves numerous feedback loops and extensive cross-talk nodes with other signaling pathways and compensatory pathways, providing ample opportunities for circumventing the effects of MEK and PI3K/mTOR inhibitors used alone or in combination with EGFR blockade. A recent excellent review recapitulates the mechanisms of primary and secondary resistance to anti-EGFR therapy and presents the numerous related clinical trials and their conclusions (Parseghian et al., 2019) . In fact, most of the resistance mechanisms revealed aberrant reactivation of key intracellular signals that were basically targeted by the drugs. For example, inhibition of AKT unexpectedly reactivated receptor tyrosine kinase signaling and expression, thereby inducing PI3K, ERK, and other crucial effectors (Chandarlapaty et al., 2011) . Several studies highlighted the importance of PI3K/AKT pathway activation as an escape mechanism underlying acquired resistance in response to an MEK inhibitor (Turke et al., 2012) or combined cetuximab/MEK therapy (Vitiello et al., 2019) in KRAS-mutated CRC cell lines.
One key finding of this study is the resensitization to cetuximab of KRAS-mutated cells using MGO scavengers. Carnosine has been previously shown to exert anti-proliferative effects against cancer cells (Iovine et al., 2012; Lee et al., 2018) , and oncolytic adenoviruses loaded with carnosine showed anti-tumor activity in vitro and in vivo (Garofalo et al., 2016) . Until recently, the potential therapeutic use of carnosine in human has been limited by serum and tissue carnosinases. Carnosinol, a stable carnosine analog with high oral bioavailability and resistant to (C) Representative pictures of the clonogenic assay performed in presence of increased concentrations of carnosine. Colonies were counted as described in STAR Methods, and numbers of colonies are presented as mean ± SEM of two independent experiments. (D) Determination of IC 50 for carnosine in SW48 CRC cells as described in STAR Methods. Data were analyzed using unpaired Student's t test and are shown as mean values ± SEM of three independent experiments. (E) Apoptosis analysis in SW48 CRC cells treated with carnosine (100 mM, 48 h) and aminoguanidine (10 and 30 mM, 48 h). Annexin-V-positive cells were quantified and shown as the percentage of apoptotic cells. All data are presented as mean values ± SEM of three independent experiments and were analyzed using one-way ANOVA followed by Bonferroni's test. (F) Cleaved PARP and cleaved caspase-3 apoptosis markers in SW48 CRC cells in parallel experiment as in E. (G) Apoptosis analysis in SW48 KRAS G12V CRC cells treated with carnosine (200 mM, 24 h) and pretreated with SC79 at the indicated concentrations for 2 h. Annexin-V-positive cells were quantified and shown as the percentage of apoptotic cells. Each fold change of percentage of apoptotic cells was quantified relative to its corresponding control condition. All data are presented as mean values ± SEM of three independent experiments and were analyzed using one-way ANOVA followed by Bonferroni's test. (H) SW48 KRAS WT and KRAS G12V CRC cells were injected subcutaneously in the flank of NOD-SCID mice (20 mice/group). Mice were treated with carnosine by intraperitoneal injection (100 mg/kg, 3 times/week). After 8 carnosine injections, mice were sacrificed and primary tumors were collected. Data are shown as mean values ± SEM. (I) Experimental tumors were subjected to IHC staining of MGO adducts, Hsp27, P-AKT, and Ki67 proliferation marker. Representative pictures of carnosine-or vehicle-(NaCl)-treated experimental tumors are shown. Scale bar represents 100 mm. (J) The proportion of experimental tumors presenting the indicated immunostaining scores (low and high) for MGO adducts, Hsp27, P-AKT, and proliferation rate Ki67, as defined in STAR Methods, is shown. Data were analyzed using one-way or two-way ANOVA depending on the number of grouping factors. Dunnett's or Bonferroni's tests were applied for simple or multiple comparisons, respectively. ***p < 0.001, **p < 0.01, and *p < 0.05; ns, not significant. See also Figure S5 . (C-E) SW48 KRAS G12V (C), HCT116 KRAS G13D (D), and LIM1215 KRAS G12V (E) CRC cells were injected subcutaneously in the flank of NOD-SCID mice (6-10 mice/ group). Mice were treated with carnosine (100 mg/kg, 3 times/week) and/or cetuximab (0.5 mg/treatment, 2 times/week). Mice were sacrificed, and tumors were collected. All data are shown as mean values ± SEM and were analyzed using two-way ANOVA.
(legend continued on next page) carnosinases, has been recently developed and proposed to treat obesity-related metabolic disorders (Anderson et al., 2018) . Considerable attention has been given to the use of natural substances as anticancer drugs. This is even more crucial when proposing combination therapeutic strategies to achieve efficacy against resistant tumors and to observe meaningful clinical benefit. Indeed, the emergence of doublet or triplet combinations tested clinically to overcome acquired resistance to cetuximab will expectedly have additional toxicities for the patients. We propose that stable carnosine analogs, such as carnosinol, administered in combination with cetuximab could be not only an effective but also a safe anti-tumor therapy. Future studies are needed to strengthen the rationale for combining anti-EGFR therapy with MGO scavengers to treat resistant glycolytic tumors harboring or not oncogenic RAS mutations. In sum, our data underscore the importance of taking into account energetic metabolic dysregulation next to tumor genotyping when stratifying CRC patients prior to EGFR-targeted therapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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The authors declare no competing interests. (Table S1) . KRAS, NRAS, BRAF, PTEN and PIK3CA mutational status of CRC tumors was assessed as described below and summarized in Table S2 . For TNM prognostic stage determination, we referred to the 7th edition of the AJCC-UICC (the American Joint Committee on Cancer and Union Internationale Contre le Cancer) that also includes grade.
Cell lines
Isogenic human CRC cell lines SW48 and LIM1215 were purchased from Horizon Discovery. The clones used were heterozygous knock-in (G12V/+) of KRAS activating mutation KRAS G12V (SW48 cat. no. HD 103-007 lot 00053 and LIM1215 cat. no. HD 116-006 lot 2874) and homozygous wild-type KRAS expressing cells (SW48 cat. no. HD PAR-006 lot 11916 and LIM1215 cat. no. HD PAR-108 lot 2706). SW48 isogenic cell lines were cultured in RPMI medium (Lonza) containing 10% fetal bovine serum (FBS, ThermoFisher Scientific) and 4.5 g/L of glucose. LIM1215 isogenic cell lines were cultivated in RPMI medium (Lonza) containing 10% fetal bovine serum (FBS, ThermoFisher Scientific), insulin (1 mg/mL), hydrocortisone (1 mg/mL) and 1 g/L of glucose. SW480, Lovo, HCT116, LS174, HT29 human CRC cell lines, all purchased from American Type Culture Collection (ATCC), were cultured in DMEM medium containing 10% FBS and 4.5 g/L of glucose. All cell lines were authenticated by STR profiling at Leibniz-Institute DSMZ (Braunschweig) and were regularly checked for mycoplasma contamination using MycoAlert mycoplasma detection kit (Lonza).
Mouse xenografts
All animal experimental procedures were performed according to the Federation of European Laboratory Animal Sciences Associations (FELASA) and were reviewed and approved by the Institutional Animal Care and Ethics Committee of the University of Liege (ethics committee approval number . Animals were housed in the GIGA-accredited animal facility (University of Liege) under standard conditions (12 hr light/dark cycle, light on at 7 a.m., food and water provided ad libitum). SW48 KRAS WT and KRAS G12V cells and HCT116 (3 3 10 6 cells/mouse) were suspended in FBS-free culture medium. LIM1215 KRAS G12V cells (2,5 3 10 6 cells/mouse) were suspended in FBS-free culture medium with matrigel (1:1 ratio). Cell suspensions were injected subcutaneously into the right posterior flanks of 7week-old immunodeficient NOD-SCID male mice (number of mice/group is as indicated in figure legend). Tumor volume was monitored three times per week using caliper and was calculated by the modified ellipsoidal formula (tumor volume = 1/2 (length 3 width 2 ). When tumors reached a volume of approximately 0.2 cm 3 , mice received intra-peritoneal injections of carnosine and/or cetuximab. Mice received carnosine three times per week (100 mg/kg/injection) and/or cetuximab twice a week (0.5 mg/injection). After 7-8 carnosine injections, mice were euthanized and tumors were collected. Tumors were fixed and embedded in paraffin for immunohistochemistry.
METHOD DETAILS
Mutational status analysis using NGS DNA was extracted from FFPE human CRC tumor samples. The regions of interest and detailed below were amplified using a laboratory developed multiplex PCR using QIAGEN multiplex PCR plus kit (QIAGEN). Molecular barcoding was performed with 'drMID DX 1-48 for Illumina NGS system' or 'drMID DX 49-96 for Illumina NGS system' (Agilent, USA) according to the manufacturer's protocol. PCR products obtained from each sample were pooled and purified using Agencourt AMPure XP beads (Beckman Coulter, USA). Each patient library was then quantified using Quanti-it Picogreen dsDNA Assay Kit (Fisher Scientific, USA) and the Fluostar Optima System (BMG Labtech, Germany). Equimolar amounts of each patient PCR products were pooled to obtain the final library. The library was then quantified and denatured according to the standard Illumina's MiSeq protocol. Sequencing was performed with a MiSeq v3 cartridge with 500 cycles (Illumina, USA). Alignment of the fastq files and variant calling were made using SeqNext 
Immunohistochemistry (IHC)
Formalin-fixed paraffin embedded sections were deparaffinized in xylene and rehydrated. Sections were treated with 3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity and washed in PBS for 20 min. Antigen retrieval was performed in sodium citrate buffer (10 mM) pH 6 at 95 C for 40 min. To block non-specific serum-binding sites, sections were then incubated with 1.5% normal serum (Vector Laboratories) for 30 min. Next, they were incubated with mouse anti-Argpyrimidine (mAb6B, 1:5000), rabbit anti-Hsp27 (Enzo Life Sciences, 1:100 dilution) rabbit anti-P-AKT (Cell signaling, 1:100 dilution) and mouse anti-Ki67 (Dako, 1:100 dilution) antibodies overnight at 4 C. Antibody binding was detected using anti-mouse or anti-rabbit biotinylated secondary antibody (Vector Laboratories) for 30 min at room temperature. Sections were then incubated with the avidin-biotin-peroxidase complex (Vectastain ABC Kit) for 30 min followed by immunoreactivity revelation with 3,3 0 diaminobenzidine tetrachloride. Slides were finally counterstained with hematoxylin, dehydrated and mounted with DPX (Sigma-Aldrich). Tissue sections incubated without primary antibody showed no detectable immunoreactivity.
Seahorse analysis
Extracellular acidification rate (ECAR) of cells was determined using Seahorse XFp extracellular flux analyzer (Agilent) according to manufacturer's recommendations and as we described previously Rademaker et al., 2018) . SW48 and LIM1215
